If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
Italian biotech SME, focused on translational oncology, discovered an innovative technology for re-engineering natural products and created a novel, organic new small molecule to be exploited for melanoma treatment. The new drug is of natural origin and comprises characterized scaffolds and pharmacophores with anti-proliferative, tumor-selective actions. Biotechnology and pharmaceutical industry are sought for license or financial agreements.
The Italian biotech company, specialized in basic and translational research for the development of
innovative technologies and drugs, has successfully performed discovery, lead identification and optimization and proof-of-concept, of a New Molecular Entity (NME) to be exploited for melanoma treatment and to be applied for the cure of patients.
The new drug discovered is an organic, oral target therapy for melanoma. It consists of an innovative technology from re-engineering natural products in a novel, organic small molecule.
In vitro tests have demonstrated the drug efficacy in halting melanoma cell proliferation, and it is tumor-selective, showing a limited effect on non-cancer cells.
It may be synergic with other existing treatments and may have the capacity to penetrate human biological barriers.
It could represent a solution for the biologic drug regards pharmacological treatment for melanoma and other skin cancers.
This biologic drug has been re-engineered from the natural compounds flavonoids.
Successfully tested in vitro has been reached with translational methodologies.
The application & customer segments are:
-- Treatment of adult patients with metastatic, not surgically removable melanoma not responding to immunotherapies or target therapies;
-- Treatment of naïve adult patients with metastatic, not surgically removable melanoma in combination with immunotherapies;
-- Treatment of adult patients with early stage melanoma at risk of unexpected progression after surgical treatment or earlier in treatment.
Biotechnology and/or pharmaceutical company or SMEs are sought for license or financial agreement.
The area of activity of the partner searched are: healthcare, pre-clinical and clinical trials, ex vivo & vitro research, tests
The main advantages are:
--drop of cancer cell proliferation;
--limited effect on non-cancer cells;
--utilized for all patient groups / skin cancers.
The bio drug is simple to manufacture and manage, and
compatible with other available treatments.
In addition the biological drug could be prescribed and commercialized through the Hospital channel, Oncologists and Dermatologists as main prescribers.
The innovative aspect is the that the biologic drug has been re-engineered from flavonoids (natural compounds).
Type of activity request for further development:
--ex vivo & vitro research: tests on 1) resistant cells from
human biopsies, 2) combinations with existing treatments, 3) long-term efficacy and 4) identification of target and all mechanism of action
--Full GLP (Good Laboratory Practices) pre-clinical trials including Acute Toxicology, Pharma kinetics and Pharmacodynamics on mice and rats
The company is open to license and collaboration agreements.
In case of license, is expected to purchase rights for the use of the patent-protected solution.
- Type of partner sought: Biotechnology and/or pharmaceutical company and/or SMEs
- Specific area of activity of the partner:
healthcare, pre-clinical and clinical trials, ex vivo & vitro research, tests on 1) resistant cells from human biopsies, 2) combinations with existing treatments, 3) long-term efficacy and 4) identification of target and all mechanism of action.
-Types of cooperation agreement:
1) financial with option of own manufacturing capacities;
2) license in this case the partner is expected to purchase rights for the use of the patent-protected solution
3) Financing for scale-up
4) Knowledge in terms of capacity and accreditation to carry out pre-clinical studies.